Innorna

Private

ShenzhenHealthcare & Life Scienceshttps://innorna.com/

Last Round

Series B

Mar 28, 2022

Total Funding Raised

$120M

Company Overview

Innorna is a biotechnology company that develops mRNA-based medicines and proprietary lipid nanoparticle (LNP) delivery systems to treat chronic diseases, power in vivo immunotherapies, and prevent infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Advanced Materials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

mRNA therapyLNP delivery platformclinical stage biotechmRNA vaccinebiopharma partnershipRNA deliverycGMP manufacturingdrug discovery platformionizable lipidsplatform licensingCMC servicesimmunotherapybiotech CDMOchemistry, manufacturing, and controls

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Innorna Comps

Public and private peers based on sector, stage, and business model.

Innorna comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Innorna Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series B	Mar 28, 2022
Series A	Jul 22, 2021
Angel	Nov 1, 2020

View all Funding Rounds

Key People

Founding team and executive leadership

Zach Zhu

Chief Technology Officer

Executive Team

Innorna Investors

Notable investors and investment history

Innorna investors
Investor	Rounds
Optimas Capital	Series B
Huasheng Capital	Series B
Legend Capital	Series A
CPE	Series B
CPE Yuanfeng	Series B
Fangyuan Capital (Hong Kong) Limited	Series B
Zhongke Chuangxing	Series A, Angel

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Oct 14, 2025
Grew 38% QoQ from 8 to 11 employees.
Jun 5, 2025
Grew 60% QoQ from 5 to 8 employees.

View all signals

Innorna Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Innorna Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Innorna's valuation, stock price, and market status.

Firmographic Details

HeadquartersShenzhen

Employee Range12

Year Founded2019

Last FundingMar 28, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.